IgG, Syn Rate,CSF
Cerebrospinal fluid (CSF)

The IgG Synthesis Rate (CSF) measures how much immunoglobulin G (IgG) is being actively produced within the central nervous system (CNS)—specifically the brain and spinal cord. It helps determine whether the immune system is generating antibodies inside the CNS, which can signal inflammation, infection, or autoimmune activity affecting the brain or spinal cord. Why it matters: While some IgG naturally crosses from the blood into the cerebrospinal fluid (CSF), an elevated IgG synthesis rate means the immune system is producing extra IgG locally within the CNS. This is a hallmark of conditions like multiple sclerosis (MS), chronic CNS infections, or autoimmune neuroinflammatory diseases. How it’s calculated: The IgG synthesis rate is calculated using levels of: IgG in the CSF and serum Albumin in the CSF and serum The result estimates how much IgG is being produced inside the CNS, rather than just leaking in from the bloodstream. What an Elevated IgG Synthesis Rate May Indicate: Multiple Sclerosis (MS): Often shows both increased synthesis rate and positive oligoclonal bands. Chronic CNS Infections: Such as HIV, syphilis, Lyme neuroborreliosis, or tuberculous meningitis. Autoimmune Diseases: Inflammatory conditions like neurosarcoidosis or lupus with CNS involvement. Other CNS disorders: Chronic inflammatory demyelinating polyneuropathy (CIDP), encephalitis. Reference Range and Interpretation: A normal IgG synthesis rate varies slightly by lab but is typically below 3.3 mg/day. A higher value suggests active immune response in the CNS and should be evaluated alongside clinical symptoms and additional tests like MRI or oligoclonal bands. Takeaway: The CSF IgG Synthesis Rate is a valuable tool in diagnosing and monitoring diseases that involve the immune system attacking or reacting within the brain or spinal cord. Elevated levels point to ongoing antibody production within the CNS, which can help confirm conditions like MS or chronic neurological infections. Interpretation should always be done by a healthcare professional in the context of a full clinical picture.

IgG/Alb Ratio, CSF
Cerebrospinal fluid (CSF)

IgG/Alb Ratio, CSF – What It Means and Why It's Important The IgG/Alb Ratio, CSF (Immunoglobulin G to Albumin Ratio in Cerebrospinal Fluid) helps evaluate immune activity within the central nervous system (CNS) and the integrity of the blood-brain barrier (BBB). It compares the levels of two key proteins—IgG and albumin—in the CSF. This ratio is particularly useful for assessing whether elevated IgG levels in the CSF are due to local immune production in the brain and spinal cord or due to leakage from the bloodstream caused by a disrupted blood-brain barrier. What Does the IgG/Albumin Ratio Measure? IgG (Immunoglobulin G): An antibody involved in immune responses. Albumin: A protein that normally remains in the bloodstream unless the blood-brain barrier is compromised. The IgG/Alb Ratio provides insight into: Intrathecal IgG synthesis (production of antibodies within the CNS) Blood-brain barrier function This ratio is often interpreted alongside the IgG Index and oligoclonal band testing in evaluating neurological diseases. What Does a High IgG/Alb Ratio in CSF Indicate? A high IgG/Albumin ratio suggests that the immune system is actively producing IgG within the CNS. This finding may be associated with: Multiple sclerosis (MS) Chronic CNS infections (e.g., neurosyphilis, Lyme disease, HIV-related neurological disease) Autoimmune disorders affecting the brain or spinal cord In these conditions, immune cells inside the CNS produce antibodies independently of the rest of the body, leading to a disproportionately high IgG level in the CSF compared to albumin. What Does a Low IgG/Alb Ratio in CSF Mean? A low or normal IgG/Alb ratio typically means: No abnormal antibody production in the CNS Intact blood-brain barrier CSF IgG levels are proportionate to what’s expected based on albumin leakage from the bloodstream This is generally considered a normal or non-pathological result. Summary The IgG/Alb Ratio, CSF helps distinguish whether elevated IgG in the cerebrospinal fluid is due to local immune activity or simply leakage through a damaged blood-brain barrier. A high ratio often points to neurological conditions like multiple sclerosis or chronic CNS infections. A normal or low ratio suggests stable immune activity and barrier integrity.

IgM B. afzelii – Research Overview IgM B. afzelii testing measures the presence of early antibodies directed against Borrelia afzelii, one of the major European subspecies of the Lyme disease–causing bacteria within the Borrelia burgdorferi sensu lato complex. While B. burgdorferi sensu stricto is most common in North America, B. afzelii is a leading cause of Lyme borreliosis in Europe and Asia. The Role of IgM Antibodies The immune system produces IgM antibodies soon after exposure to Borrelia species. In the case of B. afzelii, IgM antibodies typically appear within the first 1–3 weeks following a tick bite. Detecting IgM can indicate: Recent or early infection with B. afzelii. An ongoing immune response in symptomatic individuals. Possible non-specific reactivity or cross-reactivity, which is why results near the cut-off require careful interpretation. Clinical Significance of B. afzelii Unlike other Borrelia subspecies, B. afzelii is strongly associated with dermatological forms of Lyme disease, including: Acrodermatitis chronica atrophicans (ACA): a late-stage, chronic skin condition. Erythema migrans: the classic early “bull’s-eye” rash. Other chronic or recurrent skin manifestations. Because of these clinical patterns, detection of IgM antibodies against B. afzelii is particularly useful in European patients presenting with skin changes, joint involvement, or unexplained neurological symptoms. Limitations and Considerations False positives may occur due to cross-reactivity with other infections or immune system activity. An isolated IgM response without IgG development should be interpreted with caution, especially beyond the first 6–8 weeks of illness. For stronger diagnostic accuracy, IgM B. afzelii results should be considered alongside other Borrelia markers (e.g., B. burgdorferi sensu stricto, B. garinii, Osp proteins) and the patient’s clinical presentation. Summary The IgM B. afzelii marker helps detect early immune responses to a key European subspecies of Lyme disease. A positive result may point to a recent infection, especially when skin involvement is present, but equivocal or borderline results should be confirmed with repeat testing or additional Lyme panels. Together with clinical history and other antibody markers, this test contributes to a more accurate diagnosis of Lyme borreliosis.

IgM B. burgdorferi sensu stricto: Early Antibody Marker for Lyme Disease Overview The IgM B. burgdorferi sensu stricto (Bb ss) test detects early-stage antibodies against Borrelia burgdorferi sensu stricto, the primary bacterial species that causes Lyme disease in North America. Lyme borreliosis is a tick-borne infection that can affect the skin, joints, nervous system, and heart. The Role of IgM Antibodies IgM antibodies are among the immune system’s first responders to infection. In Lyme disease: IgM typically appears 1–2 weeks after a tick bite Peaks during the first month of infection Declines as the longer-lasting IgG response develops Detecting IgM antibodies against Borrelia burgdorferi sensu stricto can therefore indicate: A recent or early-stage infection (acute or early disseminated Lyme disease) Ongoing immune activity in patients with persistent symptoms Rarely, false-positive results or persistent IgM without IgG, which underscores the need for clinical correlation Clinical Significance A positive IgM response against Borrelia burgdorferi sensu stricto is a key diagnostic clue in early Lyme disease, particularly in patients with: Tick exposure in endemic regions Early Lyme symptoms such as erythema migrans (“bull’s-eye” rash), fever, fatigue, muscle aches, or headache Neurological signs (e.g., facial palsy, meningitis) or musculoskeletal symptoms (e.g., joint pain, early arthritis) that arise within weeks of infection If untreated, early Lyme infection can progress to Lyme arthritis, neuroborreliosis, or Lyme carditis. Early recognition through IgM testing supports timely treatment and reduces the risk of complications. Limitations and Considerations While IgM testing is valuable, results require cautious interpretation: False positives may occur due to cross-reactivity with other infections or autoimmune conditions Isolated IgM positivity without subsequent IgG conversion—especially beyond 6–8 weeks after symptom onset—may not reflect active infection Confirmatory testing with additional Borrelia antigens (e.g., Osp proteins) or co-infection panels improves diagnostic accuracy Summary The IgM B. burgdorferi sensu stricto test provides important insight into the early immune response to Lyme disease. A positive result suggests recent or current infection, but interpretation should always be based on clinical presentation, exposure history, and other laboratory findings. As part of the broader Lyme immunoserology panel, this marker helps guide earlier detection and management of Lyme disease.

IgM B. burgdorferi Antigen (AG) Test: Early Antibody Marker for Lyme Disease Overview The IgM B. burgdorferi Antigen (AG) test detects early-stage antibodies against Borrelia burgdorferi, the spirochete bacterium responsible for Lyme disease. Unlike subspecies- or protein-specific assays, this test measures IgM antibodies directed against a broader set of Borrelia antigens, improving sensitivity and making it a valuable tool in the early detection of Lyme borreliosis. The Role of IgM Antibodies IgM is the first class of antibodies produced by the immune system during infection. In Lyme disease: IgM typically appears 1–2 weeks after a tick bite Peaks during the first month of infection Declines as IgG antibodies become more dominant Measuring IgM against Borrelia antigens provides insight into a recent or active immune response, making it particularly useful in identifying early-stage infection. Clinical Significance A positive IgM response against B. burgdorferi antigens suggests a possible recent infection. This is especially relevant for patients with: Early Lyme symptoms such as erythema migrans (bull’s-eye rash), fever, fatigue, headache, or muscle aches Neurological manifestations including cranial neuritis, meningitis, or cognitive changes Musculoskeletal involvement such as migratory joint pain or early Lyme arthritis Because IgM reflects the early immune response, this marker can support recognition of Lyme disease before complications such as arthritis, carditis, or neuroborreliosis develop. Limitations and Considerations False positives may occur due to cross-reactivity with other infections or autoimmune conditions Isolated IgM positivity without subsequent IgG development, particularly beyond 6–8 weeks of symptoms, may not indicate active infection Persistent IgM antibodies can be detected in some individuals even after treatment, making clinical context essential Additional testing with subspecies markers (B. afzelii, B. garinii) or antibodies to Outer Surface Proteins (OspA, OspC, OspE) can improve diagnostic accuracy when interpreted alongside IgM AG results Broader Context in Lyme Testing Traditional Lyme serology, such as ELISA and Western Blot, measures antibodies to mixtures of Borrelia proteins. While sensitive, these methods may lack specificity. Newer multi-antigen ELISA and next-generation immunoserology approaches combine cultured Borrelia antigens with in vivo–expressed proteins, allowing for more precise differentiation between Lyme disease and other conditions. The IgM B. burgdorferi AG test remains a foundational early marker within this broader testing strategy. Summary The IgM B. burgdorferi Antigen (AG) test captures the body’s early antibody response to Lyme disease. A positive result may support the diagnosis of a recent or ongoing infection, but it should never be interpreted in isolation. Results are most informative when combined with clinical history, symptom timing, IgG antibodies, and confirmatory testing. As part of a comprehensive serologic panel, this marker plays a key role in the early identification and management of Lyme disease, helping to prevent progression to later-stage complications.

Overview The IgM B. garinii test detects early antibodies against Borrelia garinii, a key subspecies within the Borrelia burgdorferi sensu lato complex that causes Lyme disease. While B. burgdorferi sensu stricto is the primary agent in North America, B. garinii is most common in Europe and parts of Asia, where it is strongly associated with neurological forms of Lyme disease (neuroborreliosis). The Role of IgM Antibodies IgM is the first antibody class produced by the immune system during infection. In Lyme disease: IgM antibodies typically appear 1–3 weeks after a tick bite They peak in the first month of infection Often decline as IgG antibodies develop Detection of IgM antibodies specific to B. garinii suggests a recent immune response and supports early recognition of infection, particularly in neurological cases. Clinical Significance of B. garinii Borrelia garinii is notable for its neurotropism (tendency to affect the nervous system). Clinical associations include: Lymphocytic meningitis (headache, neck stiffness, fever) Cranial neuritis, particularly facial palsy Radiculoneuritis (nerve pain, tingling, or weakness) Cognitive or memory disturbances in disseminated infection Although primarily linked with neuroborreliosis, B. garinii can occasionally present with joint or cardiac involvement. A positive IgM B. garinii result is therefore especially relevant in patients with neurological symptoms after tick exposure in endemic areas. Limitations and Considerations False positives can occur due to cross-reactivity Timing matters: best interpreted within the first month Beyond 6–8 weeks, isolated IgM without IgG is less reliable Geography matters: highly relevant in Europe/Asia, less so in North America unless travel is involved Confirmatory testing (IgG antibodies, Osp proteins, subspecies assays) improves accuracy Broader Context in Lyme Testing Different Borrelia subspecies drive different disease patterns: B. afzelii → mainly skin involvement B. burgdorferi sensu stricto → joint disease B. garinii → neurological involvement Including IgM B. garinii in European Lyme panels increases diagnostic precision by capturing the neurological spectrum of the disease. Summary The IgM B. garinii test identifies early antibody responses to a subspecies strongly linked to neurological Lyme disease in Europe and Asia. A positive result may reflect a recent or ongoing infection, especially in patients with neurological symptoms following tick exposure. Because cross-reactivity and false positives are possible, results should always be interpreted with clinical history, geography, and confirmatory Lyme testing.

Overview The IgM B. miyamotoi test measures early antibodies against Borrelia miyamotoi, a spirochete related to the Borrelia burgdorferi sensu lato complex but classified within the relapsing fever group of Borrelia, rather than the classical Lyme-associated species. First identified in Japan in 1995, B. miyamotoi is now recognized in North America, Europe, and Asia as an emerging tick-borne pathogen transmitted by the same Ixodes ticks that spread Lyme disease. The Role of IgM Antibodies IgM antibodies are part of the immune system’s first response to infection. In B. miyamotoi disease (BMD), IgM typically becomes detectable within days to weeks of symptom onset. Since BMD often presents as an acute, flu-like illness with relapsing fever episodes, early IgM detection is an important indicator of recent or ongoing infection. Clinical Significance of B. miyamotoi Borrelia miyamotoi causes Borrelia miyamotoi disease (BMD), which shares clinical features with both Lyme disease and tick-borne relapsing fever. Characteristic findings include: Flu-like symptoms: fever, chills, fatigue, muscle aches, headache Relapsing fever: recurrent febrile episodes, typical of relapsing fever Borrelia Neurological complications, such as meningoencephalitis, especially in immunocompromised patients Absence of erythema migrans: unlike Lyme disease, BMD usually does not present with the bull’s-eye rash Because BMD overlaps with other tick-borne illnesses but lacks hallmark Lyme signs, IgM testing helps clinicians suspect and identify this distinct infection. Limitations and Considerations Cross-reactivity: Antibodies may react with Lyme-related Borrelia antigens; specific testing helps distinguish BMD from Lyme disease. Timing: IgM is most informative early; in longer illness courses, IgG testing may be more reliable. Emerging recognition: As a relatively new pathogen, clinical experience and diagnostic access are more limited than for classical Lyme. Geographic relevance: Positive results are most meaningful where Ixodes ticks are common (North America, Europe, Asia), and must be interpreted in light of exposure history. Broader Context in Tick-Borne Illness The discovery of B. miyamotoi underscores that tick-borne diseases extend beyond Lyme disease alone. Ixodes ticks can transmit Borrelia burgdorferi, Anaplasma, Babesia, and B. miyamotoi, making co-infections possible and often complicating clinical presentation. Including IgM B. miyamotoi testing alongside other tick-borne panels provides a more complete assessment when evaluating patients with fever, relapsing symptoms, or neurological issues after tick exposure. Summary The IgM B. miyamotoi test detects early antibody responses to a relapsing fever–type Borrelia increasingly recognized as an emerging human pathogen. A positive result suggests a recent or active infection, typically presenting as relapsing fever with flu-like illness, and in some cases, neurological involvement. Because B. miyamotoi disease differs clinically from classical Lyme borreliosis, results should always be interpreted in the context of symptoms, exposure history, and confirmatory testing for other tick-borne pathogens.

IgM Babesia
Serum

Overview The IgM Babesia test detects early antibodies against Babesia species, a group of tick-borne protozoan parasites that infect red blood cells. Unlike Lyme disease, caused by Borrelia bacteria, babesiosis is a malaria-like illness most commonly linked to Babesia microti in North America and Babesia divergens or Babesia venatorum in Europe. By destroying red blood cells, Babesia can cause illness ranging from mild fatigue to life-threatening infection in at-risk patients. The Role of IgM Antibodies IgM antibodies are the first line of immune defense against infection. In babesiosis, IgM typically appears within 1–2 weeks of exposure, serving as an early marker of recent or acute infection. Because Babesia parasites can persist in circulating red blood cells, IgM testing helps identify cases early, sometimes before IgG antibodies or confirmatory findings are detectable. Clinical Significance of Babesia Infection The severity of babesiosis varies widely depending on patient age, immune status, and splenic function. Clinical features include: Flu-like illness: fever, chills, sweats, headache, fatigue Hemolytic anemia: pallor, jaundice, or shortness of breath from red blood cell destruction Splenomegaly: enlarged spleen in more advanced or severe cases Severe disease: immunocompromised patients, the elderly, or those without a spleen are at highest risk for multi-organ failure, high parasite burden, and death if untreated Early detection by IgM markers is particularly important in these vulnerable groups. Limitations and Considerations Cross-reactivity: IgM antibodies may show low-level reactivity or persist, limiting specificity. Confirmatory testing: Diagnosis is generally supported by blood smear microscopy, PCR, or IgG testing. Co-infections: Because Ixodes ticks can also carry Borrelia (Lyme) and Anaplasma, co-infections are common and may complicate disease presentation and management. Geographic distribution: B. microti predominates in the Northeastern and upper Midwestern U.S., while severe B. divergens infections are more typical in Europe. Broader Context in Tick-Borne Disease Babesiosis fits into the broader spectrum of tick-borne illnesses, often occurring alongside Lyme disease from the same tick bite. While Lyme primarily targets connective tissues and nerves, Babesia destroys red blood cells, leading to hemolytic complications. Recognition of IgM Babesia is critical for distinguishing co-infections, since treatment requires antiparasitic therapy (e.g., atovaquone plus azithromycin or clindamycin plus quinine in severe cases) rather than antibiotics alone. Summary The IgM Babesia test identifies the body’s early immune response to infection with Babesia parasites. A positive result suggests recent or active babesiosis, which may range from mild flu-like illness to severe, life-threatening disease in high-risk individuals. Because co-infections with Lyme disease and other tick-borne pathogens are common, IgM results should always be interpreted in the context of symptoms, confirmatory testing, and exposure risk, helping clinicians recognize babesiosis as a distinct and important tick-borne infection requiring targeted therapy.

The IgM Bartonella test detects early antibodies against Bartonella species, a group of bacteria transmitted by ticks, fleas, lice, or scratches from infected animals (especially cats). The most common human pathogens are Bartonella henselae and Bartonella quintana, which can cause cat scratch disease, trench fever, or tick-borne bartonellosis. In some cases, Bartonella infections may contribute to chronic fatigue, neurological issues, or joint pain, especially when co-infections with Lyme disease or Babesia are present. What IgM Bartonella Means IgM antibodies are the body’s first response to infection and usually appear within the first 1–3 weeks after exposure. A positive IgM Bartonella result suggests a recent or active infection. Because IgM may decline over time, this test is most reliable during the early stages of infection. Clinical Importance Testing for IgM Bartonella may be most useful in patients who have: Acute symptoms such as fever, swollen lymph nodes, fatigue, or muscle aches Neurological problems like headaches, neuropathy, or cognitive changes Skin or eye inflammation sometimes linked to Bartonella infection Recent tick, flea, or cat exposure in areas where Bartonella is known to circulate Patient Takeaway A positive IgM Bartonella result suggests that your immune system is currently fighting or has very recently fought a Bartonella infection. However, IgM antibodies alone are not enough to confirm the diagnosis, since false positives and cross-reactions can occur. Your healthcare provider will interpret this result alongside your symptoms, exposure history, and other tests (such as IgG, PCR, or culture-based methods). If your IgM result is equivocal (borderline), antibody levels are near the cutoff and the finding is uncertain. In these cases, repeat or confirmatory testing is often recommended.

IgM Cytomegalovirus (CMV) measures the level of IgM antibodies, which are the body’s first line of defense when encountering a virus. These antibodies typically appear during a new CMV infection or during viral reactivation. Because CMV is a common virus—often acquired in childhood—IgM testing helps determine whether your immune system is responding to a recent or ongoing infection. CMV IgM is often used together with CMV IgG, clinical symptoms, or PCR testing to clarify whether the infection is new, reactivating, or clinically significant. What It Means When Your IgM CMV Result Is Within the Reference Range (Negative) A negative or normal IgM CMV result means there is no evidence of a recent or active CMV infection at the time of testing. When IgM is within the reference range: Your immune system is not producing new CMV-specific IgM antibodies. There is no laboratory indication of a current or very recent infection. Viral reactivation is unlikely based on this marker alone. If you have CMV IgG antibodies, they reflect past exposure only, not new illness. A negative IgM result is reassuring and is the most common finding in healthy individuals.

IgM EB Nuclear Antigen (EBNA IgM) measures early antibodies directed against the Epstein–Barr Virus (EBV) Nuclear Antigen. Unlike other EBV markers, such as VCA IgM, EBNA IgM is not commonly produced and is generally not a standard marker of acute infection. When it does appear, it may indicate an early-phase immune response, but it is less specific and less commonly used in clinical decision-making. Because EBNA proteins are expressed later in the EBV life cycle, IgM antibodies to EBNA are rarely detected during typical EBV infections. For this reason, clinicians rely more heavily on VCA IgM, VCA IgG, EBNA IgG, and Early Antigen when evaluating EBV activity. EBNA IgM can sometimes be included in extended EBV panels to help rule out atypical or early immune responses. What It Means When Your EBNA IgM Result Is Within the Reference Range (Negative) A negative or normal EBNA IgM result means there is no evidence of a recent or acute immune response to the EBV Nuclear Antigen. In practical terms, this indicates: Your immune system is not producing early-phase EBNA-specific IgM antibodies. There is no laboratory support for an active or newly developing EBV infection based on this marker. This result is consistent with the vast majority of healthy individuals, as EBNA IgM is typically not elevated even during routine EBV infections. When EBNA IgM is within the reference range: EBV infection is unlikely to be recent. If other EBV markers (VCA IgM, EA IgG) are also negative, it supports the conclusion that EBV is not active. Past infection—if present—would be reflected in EBNA IgG, not in this marker. A negative EBNA IgM result is expected and reassuring, especially in the absence of symptoms suggestive of acute mononucleosis.

Overview The IgM Ehrlichia test detects early antibody responses to infection with Ehrlichia species, tick-borne intracellular bacteria that infect white blood cells and cause ehrlichiosis. The main human pathogens are Ehrlichia chaffeensis (causing human monocytic ehrlichiosis, HME) and Ehrlichia ewingii. Ehrlichiosis is most common in the southeastern and south-central United States, but cases are also reported in other tick-endemic regions worldwide. The Role of IgM Antibodies IgM antibodies are the earliest detectable immune response, usually appearing within the first 1–2 weeks of illness. In ehrlichiosis, detection of IgM can suggest recent or acute infection, particularly when consistent symptoms are present. However, IgM alone is not a definitive marker since low levels may appear late and cross-reactivity with other infections is possible. Clinical Significance of Ehrlichiosis Ehrlichiosis is an acute febrile illness ranging from mild to life-threatening. Symptoms generally develop 1–2 weeks after a tick bite, and may include: Flu-like illness: fever, chills, severe headache, muscle aches, fatigue Gastrointestinal symptoms: nausea, vomiting, abdominal pain Neurological findings: confusion, meningitis, seizures in severe cases Laboratory abnormalities: leukopenia, thrombocytopenia, and elevated liver enzymes Patients at highest risk for severe disease include older adults, immunocompromised individuals, and those with delayed treatment, who may develop respiratory failure, bleeding disorders, or multi-organ involvement. Limitations and Considerations Early testing challenge: IgM may be absent in the first few days despite active infection, reinforcing the importance of clinical suspicion. False positives: Cross-reactivity with antibodies from other tick-borne pathogens may lead to nonspecific IgM results. Confirmatory testing: PCR during the acute phase or IgG seroconversion in paired samples offers stronger diagnostic evidence. Treatment urgency: Because ehrlichiosis can progress rapidly, empiric therapy with doxycycline is recommended without waiting for test confirmation. Broader Context in Tick-Borne Disease Ehrlichiosis is one of several serious infections transmitted by the lone star tick (Amblyomma americanum) and related species. Co-infection with Lyme disease, Anaplasma, or Babesia is possible, and overlapping symptoms may complicate diagnosis. Including IgM Ehrlichia testing within a tick-borne disease panel allows clinicians to identify and manage these complex cases more effectively. Summary The IgM Ehrlichia marker identifies early immune responses to a potentially severe tick-borne illness. A positive result suggests recent or acute infection, often accompanied by fever, abnormal blood counts, and systemic symptoms. Because ehrlichiosis can progress quickly if untreated, results must always be interpreted in conjunction with clinical findings, confirmatory testing, and timely medical care.

IgM Epstein–Barr Virus Viral Capsid Antigen (EBV VCA IgM) measures early antibodies produced by the immune system during a new or recent Epstein–Barr virus infection. EBV is a common virus best known for causing infectious mononucleosis (“mono”), especially in adolescents and young adults. VCA IgM antibodies are typically: Detectable during the acute phase of infection Present for only a short period (usually several weeks) Used to help identify whether symptoms—such as fatigue, swollen lymph nodes, sore throat, or fever—are related to a current EBV infection Because IgM rises quickly and declines relatively fast, it is a key marker for determining if EBV infection is occurring now or very recently. What It Means When Your IgM EBV VCA Result Is Within the Reference Range (Negative) A negative or normal IgM EBV VCA result means there is no evidence of a recent or active Epstein–Barr virus infection at the time of testing. When this marker is within the reference range: Your immune system is not producing early, active-phase EBV antibodies. There is no laboratory indication of a current mono-like infection. Any past exposure you may have had is not recent—and would instead be reflected in EBV IgG markers, not IgM. This result is reassuring and is the most common finding in individuals without active symptoms. A negative IgM result is especially helpful when interpreting the rest of the EBV panel; it supports the conclusion that EBV is not driving current symptoms. If symptoms persist, clinicians may look at additional markers—such as EBV EBNA IgG, EBV VCA IgG, or Early Antigen (EA)—to build a more complete picture.

Overview The IgM Immunodominant C6 (IR6) test detects early antibodies against the conserved C6 peptide, a 26–amino acid sequence from the invariable region (IR6) of VlsE, the variable surface antigen in Borrelia burgdorferi sensu lato. While VlsE undergoes domain variation to evade the immune system, the IR6 region remains highly conserved across Lyme-causing subspecies (B. burgdorferi sensu stricto, B. afzelii, B. garinii). This conservation makes C6-based assays valuable broad-spectrum markers in Lyme serology. Why IgM to C6 Matters Early signal of infection: IgM antibodies are the first to rise after exposure, and anti-C6 IgM can appear within 1–3 weeks of a tick bite, indicating early or recent infection. Cross-subspp coverage: Because the C6 epitope is conserved, the assay can detect immune responses across diverse Borrelia subspecies in North America, Europe, and parts of Asia. Diagnostic utility: Evaluations of C6 ELISA show high sensitivity in acute infection (increasing into convalescence) and strong specificity, supporting its rule-in value when combined with compatible symptoms and exposure risk. Clinical Significance A positive IgM C6 suggests an early immune response to Lyme borreliosis, particularly valuable for patients with: Early localized or disseminated disease: erythema migrans, fever, headache, myalgia, fatigue Neurological presentations: meningitis, cranial neuritis, radiculoneuritis Musculoskeletal involvement: migratory arthralgias or evolving arthritis Because C6 can be measured quantitatively, serial testing may support follow-up, though antibody kinetics vary and serology should not be used alone to monitor treatment response. Limitations and Interpretation Caveats Timing: IgM is most informative within the first month; isolated IgM beyond 6–8 weeks without IgG warrants caution (may reflect non-specific reactivity or past exposure). Cross-reactivity: Though designed for specificity, occasional reactivity occurs (e.g., autoimmune triggers or other Borrelia species). Notably, C6 reactivity has been described in Borrelia miyamotoi (a relapsing fever–group spirochete). No subspecies resolution: C6 reflects pan-Borrelia exposure but does not identify the infecting strain or stage of disease. Clinical context required: A positive C6 IgM alone does not confirm active Lyme. Integration with exposure history, symptoms, exam findings, confirmatory markers (VlsE/whole-cell EIAs, immunoblots, Osp proteins, subspecies-specific antigens), and co-infection assessment (Babesia, Anaplasma/Ehrlichia, Bartonella) is essential. Role in Modern Lyme Testing C6 assays are increasingly used in modified two-tier Lyme testing algorithms, valued for their broad coverage and strong analytic performance. In multi-antigen ELISA panels, IgM C6 complements other markers such as OspC, VlsE/DbpA, and subspecies-specific assays, enhancing early detection while maintaining high specificity across the clinical spectrum. Summary The IgM Immunodominant C6 marker is a conserved, early-phase Lyme serology tool that captures recent immune responses across major Borrelia subspecies. It offers strong diagnostic value in acute disease but requires careful interpretation, particularly when IgM is isolated or when cross-reactivity is considered. Most powerful when paired with compatible symptoms, exposure history, and complementary serology, IgM C6 serves as a core element of modern multi-antigen Lyme testing strategies.

Overview The IgM LFA Antigen + CK10 test looks at two parts of the immune system: how your body responds to infections in the short term and whether it may be reacting against its own tissues (autoimmunity). It does this by measuring IgM antibodies (early infection fighters) and antibodies against Cytokeratin 10 (CK10), a protein found in the skin and other epithelial tissues. What IgM Antibodies Tell Us IgM is the first antibody type your body produces when it fights off a new infection. Finding IgM in this test can signal a recent or ongoing infection, such as from a virus, bacteria, or parasite. Normally, IgM is later replaced by longer-lasting IgG antibodies. If IgM stays high for too long, it may point to continued immune activity or a possible autoimmune process. What CK10 Antibodies Mean CK10 is a protein that helps give structure to skin cells. Sometimes the immune system mistakenly produces antibodies against CK10, which may happen in conditions such as: Autoimmune skin diseases (like pemphigus or pemphigoid) Psoriasis or chronic skin inflammation Conditions where the skin barrier is damaged and the immune system targets exposed proteins These antibodies can be a clue that the immune system is mistakenly attacking the body’s own tissues. Why Combining IgM and CK10 Matters By looking at both infection-related IgM and CK10 autoantibodies, this test helps healthcare providers and researchers: Differentiate between symptoms caused by infections vs. autoimmunity Detect immune activity early, before long-term tissue damage occurs Explore how infections might trigger autoimmune reactions, which is a growing area of research in chronic inflammatory and autoimmune diseases Key Takeaways IgM antibodies help show if your body is currently fighting an infection. CK10 antibodies may suggest the immune system is attacking skin or epithelial cells. Together, these results give a clearer picture of whether symptoms are driven by infection, autoimmunity, or a combination of both.

IgM Outer Surface Protein A + C (OspA + OspC) The IgM OspA + OspC test detects early immune responses to Borrelia burgdorferi, the bacteria responsible for Lyme disease. It looks for IgM antibodies against two key surface proteins: OspC (Outer Surface Protein C): Produced in the early stages of infection. OspA (Outer Surface Protein A): More often associated with later or persistent infection. Because Borrelia expresses these proteins at different points in its life cycle, testing for both can provide a broader picture of the stage and progression of Lyme disease. What the Results Mean OspC IgM antibodies: Typically appear within 2–3 weeks after a tick bite, making them a strong marker for recent Lyme infection. OspA IgM antibodies: More often linked with later or persistent disease, and sometimes with chronic or autoimmune-like manifestations of Lyme. When considered together, OspA and OspC testing helps clinicians estimate where a patient may be along the Lyme disease timeline. Clinical Importance This test may be most helpful for patients who present with: Early Lyme symptoms such as fever, rash (erythema migrans), fatigue, headache, or muscle aches Neurological involvement including facial palsy, meningitis-like symptoms, or nerve pain Joint pain or swelling that develops weeks to months after exposure Documented tick bites or exposure in areas where Lyme disease is common Limitations IgM reliability is time-sensitive: IgM is most useful in the early weeks of infection. Isolated IgM positivity months later may not indicate active infection. False positives can occur due to cross-reactivity with other bacterial or viral infections. Confirmatory testing is standard: Additional markers such as IgG antibodies, VlsE/C6 peptide, or multi-antigen panels are often used to strengthen diagnostic accuracy. Patient Takeaway A positive IgM OspA + OspC test means your immune system is producing early antibodies against Borrelia, suggesting possible recent or ongoing exposure to the bacteria that causes Lyme disease. However, this test alone does not confirm Lyme disease. Your doctor will always interpret the results in the context of: Your symptoms Tick exposure history Other Lyme disease test results If your test is reported as equivocal (borderline), it means antibody levels are close to the cutoff and not clearly positive or negative. In these cases, your provider may recommend repeat testing or additional confirmatory panels.

The IgM OspE test detects early antibodies against Outer Surface Protein E (OspE) of Borrelia burgdorferi, the bacterium responsible for Lyme disease. OspE belongs to the Erp (OspE-related proteins) family, which helps Borrelia survive in the human bloodstream by binding to factor H, a host protein that protects the bacteria from complement-mediated killing. What IgM OspE Means IgM antibodies usually appear within the first 1–3 weeks after infection, making this test useful for detecting early or recent exposure to Borrelia. A positive IgM OspE result suggests that the immune system is actively responding to Borrelia at the early stage of infection. Because OspE is associated with immune evasion, antibody detection may indicate Borrelia dissemination in the bloodstream. Clinical Importance Testing for IgM OspE can be helpful in patients who have: Early Lyme symptoms such as fever, rash, fatigue, headache, or muscle aches Neurological or joint issues appearing shortly after suspected infection Recent tick exposure in areas where Lyme disease is common Unexplained immune activation that overlaps with Lyme-like presentations Patient Takeaway A positive IgM OspE result suggests your immune system has recently recognized Borrelia, pointing to a new or active infection. However, since IgM testing can sometimes produce false positives or cross-react with other infections, it is not considered diagnostic on its own. Your healthcare provider will interpret the result alongside your symptoms, history of tick exposure, and other Lyme disease markers (such as OspC, OspA, or VlsE/C6). If your IgM OspE test result is equivocal (borderline), antibody levels are near the cutoff and the finding is uncertain. In such cases, repeat or confirmatory testing is usually recommended.